#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    B-cell lymphoma refractory Neuroblastoma Neoplasm malignant Congenital nephrogenic diabetes insipidus Osteopetrosis Thermal burn Gastrooesophageal cancer Essential thrombocythaemia Chordoma Adrenocortical carcinoma Glycogen storage disease type I Factor VIII deficiency Bulbospinal muscular atrophy congenital Optic glioma Spina bifida More trials…

    Learn about Rare Diseases

    Anaplastic thyroid cancer – Life with Disease Antisynthetase syndrome – Diagnostics Pleural mesothelioma malignant Mastocytosis – Basic Information Gaucher’s disease type I – Trials in Disease Haemophilia A with anti factor VIII – Treatment CADASIL – Life with Disease Behcet’s syndrome Mantle cell lymphoma stage IV – Trials in Disease Hairy cell leukaemia More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Indocyanine Green Panitumumab Ociperlimab VELPATASVIR Aspartic Acid Msv/As Donidalorsen Mva-209-Fsp-B3 Human Plasma Protein Decitabine Depemokimab Beclometasone Dipropionate Levodropropizine Milvexian Paracetamol Dc STREPTOCOCCUS VIRIDANS Daridorexant Antiemetics And Antinauseants Riliprubart Istaroxime More therapies…

    Learn about Your Condition

    Depression Mastocytosis Colitis ulcerative Periodontitis Tumour of ampulla of Vater Colour blindness Acute respiratory failure Breast proliferative changes Cervical dysplasia Breast cancer stage III Foot deformity Nephrotic syndrome Follicular lymphoma stage IV Head and neck cancer Squamous cell carcinoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hemic and Lymphatic Diseases

  • Study on Venetoclax and Azacitidine for Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Myelodysplastic syndrome
    Investigated Drugs:
    • Azacitidine
    • Venetoclax
    Austria Belgium Czechia France Germany Italy +3

  • Study on the Safety and Effects of BAY 2599023 (Peboctocogene Camaparvovec) for Adults with Severe Hemophilia A

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Factor VIII deficiency
    Investigated Drugs:
    • Peboctocogene Camaparvovec
    Bulgaria France Germany The Netherlands

  • Study on Lenalidomide, Tafasitamab, and Rituximab for Treating Diffuse Large B-Cell Lymphoma in Patients Aged 80 and Older

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Tafasitamab
    • Cyclophosphamide
    • Doxorubicin
    Belgium France

  • Study on Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Low-Risk Multiple Myeloma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Betamethasone Sodium Phosphate Ph. Eur
    • Isatuximab
    • Bortezomib
    Germany

  • Study of Tolinapant with Decitabine and Cedazuridine for Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

    Not recruiting

    1 1 1
    Investigated Drugs:
    • Cedazuridine
    • Decitabine
    • Tolinapant Lactate
    France Hungary Italy Poland Spain

  • Study to Compare Mezigdomide, Carfilzomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Mezigdomide
    • Carfilzomib
    • Dexamethasone
    Austria Bulgaria Denmark Germany Greece Hungary +5
Previous Page
1 … 78 79 80 81 82 … 89
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!